MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States


MDxHealth Launches SelectMDx "Liquid Biopsy" Test in the United States

Non-invasive, urine-based prostate cancer assay available as a laboratory developed test

IRVINE, CA, and HERSTAL, BELGIUM – March 17, 2016 – MDxHealth SA (Euronext: MDXH.BR), today announced the commercial launch of its SelectMDx™ for Prostate Cancer test in the United States as a laboratory developed test (LDT). Testing will be conducted at MDxHealth's state-of-the-art CAP and CLIA accredited laboratory facilities in Irvine, California.

The proprietary SelectMDx test has been validated as a urine-based, non-invasive 'liquid biopsy' method to identify men at risk for aggressive, potentially lethal, prostate cancer who may benefit from an initial prostate biopsy or magnetic resonance imaging (MRI) and early detection. With a negative predictive value (NPV) of 98% for high-grade disease, SelectMDx also helps identify men at very low risk for clinically significant cancer, and could reduce unnecessary invasive biopsies by approximately 50%, thereby decreasing healthcare costs.

"Following the successful European launch of SelectMDx in late 2015, we are excited to introduce the test in the US market, complementing our existing ConfirmMDx® tissue based diagnostic test for repeat biopsy," stated Dr. Jan Groen, Chief Executive Officer of MDxHealth. "This marks another key milestone in our commercial strategy to provide the urology community with well-validated and powerful molecular diagnostic solutions which address unmet medical needs for cancer patients."

SelectMDx will be marketed in the US through MDxHealth's direct national sales force of over 37 representatives and managers to the Company's established and growing customer base of urologists and managed care providers.

About SelectMDxTM for Prostate Cancer

Of the nearly 2 million prostate biopsies performed each year, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated side effects and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to identify patients at low risk for prostate cancer, helping to both reduce unnecessary prostate biopsy procedures with their associated complications and expense and to identify those men at increased risk of harbouring high-grade disease who may benefit most from earlier detection.

About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic and epigenetic (methylation) molecular technologies and assist physicians with the diagnosis of urological cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit and follow us on Twitter at:
For more information:


Dr. Jan Groen, CEO


US: +1 949 812 6979

BE: +32 4 364 20 70




Amber Fennell, Chris Welsh, Hendrik Thys (PR & IR)

Consilium Strategic Communications

UK: +44 20 3709 5701

Cell: + 44 7739658783